Athira Pharma Inc (ATHA)
2.60
+0.06
(+2.36%)
USD |
NASDAQ |
Jun 17, 16:00
2.56
-0.04
(-1.54%)
Pre-Market: 20:00
Athira Pharma Enterprise Value: -22.43M for June 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 17, 2024 | -22.43M |
| June 14, 2024 | -24.73M |
| June 13, 2024 | -24.35M |
| June 12, 2024 | -22.43M |
| June 11, 2024 | -24.35M |
| June 10, 2024 | -24.35M |
| June 07, 2024 | -24.35M |
| June 06, 2024 | -24.73M |
| June 05, 2024 | -23.58M |
| June 04, 2024 | -28.57M |
| June 03, 2024 | -24.35M |
| May 31, 2024 | -21.67M |
| May 30, 2024 | -25.12M |
| May 29, 2024 | -24.35M |
| May 28, 2024 | -23.97M |
| May 24, 2024 | -20.90M |
| May 23, 2024 | -23.97M |
| May 22, 2024 | -21.67M |
| May 21, 2024 | -24.73M |
| May 20, 2024 | -25.50M |
| May 17, 2024 | -25.50M |
| May 16, 2024 | -18.22M |
| May 15, 2024 | -37.38M |
| May 14, 2024 | -37.76M |
| May 13, 2024 | -33.55M |
| Date | Value |
|---|---|
| May 10, 2024 | -40.83M |
| May 09, 2024 | -37.00M |
| May 08, 2024 | -40.07M |
| May 07, 2024 | -38.54M |
| May 06, 2024 | -46.58M |
| May 03, 2024 | -46.97M |
| May 02, 2024 | -46.97M |
| May 01, 2024 | -43.90M |
| April 30, 2024 | -46.58M |
| April 29, 2024 | -46.58M |
| April 26, 2024 | -48.50M |
| April 25, 2024 | -48.50M |
| April 24, 2024 | -45.05M |
| April 23, 2024 | -43.90M |
| April 22, 2024 | -41.99M |
| April 19, 2024 | -40.45M |
| April 18, 2024 | -43.14M |
| April 17, 2024 | -41.22M |
| April 16, 2024 | -41.22M |
| April 15, 2024 | -43.14M |
| April 12, 2024 | -28.57M |
| April 11, 2024 | -20.52M |
| April 10, 2024 | -27.04M |
| April 09, 2024 | -25.50M |
| April 08, 2024 | -29.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-160.40M
Minimum
Jun 24 2022
927.96M
Maximum
Dec 31 2020
97.56M
Average
-23.85M
Median
Enterprise Value Benchmarks
| Xeris Biopharma Holdings Inc | 465.52M |
| Kodiak Sciences Inc | -104.60M |
| Phathom Pharmaceuticals Inc | 511.66M |
| Inozyme Pharma Inc | 163.41M |
| LENZ Therapeutics Inc | 257.58M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.34M |
| Total Expenses (Quarterly) | 27.69M |
| EPS Diluted (Quarterly) | -0.69 |
| Earnings Yield | -117.3% |